Bristol Myers Squibb Company $BMY Shares Bought by Sterling Capital Management LLC

Sterling Capital Management LLC raised its stake in Bristol Myers Squibb Company (NYSE:BMY) by 4.3% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 229,996 shares of the biopharmaceutical company’s stock after acquiring an additional 9,542 shares during the period. Sterling Capital Management LLC’s holdings in Bristol Myers Squibb were worth $14,352,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of the stock. XXI Wealth LLC raised its holdings in Bristol Myers Squibb by 87.4% in the 3rd quarter. XXI Wealth LLC now owns 30,096 shares of the biopharmaceutical company’s stock worth $1,878,000 after acquiring an additional 14,039 shares during the last quarter. BIP Wealth LLC raised its stake in Bristol Myers Squibb by 6.7% during the 3rd quarter. BIP Wealth LLC now owns 5,528 shares of the biopharmaceutical company’s stock valued at $345,000 after buying an additional 348 shares during the last quarter. Patrick M Sweeney & Associates Inc. increased its position in Bristol Myers Squibb by 10.7% during the third quarter. Patrick M Sweeney & Associates Inc. now owns 9,171 shares of the biopharmaceutical company’s stock valued at $572,000 after acquiring an additional 885 shares during the last quarter. MBL Wealth LLC lifted its stake in shares of Bristol Myers Squibb by 17.0% in the 3rd quarter. MBL Wealth LLC now owns 9,719 shares of the biopharmaceutical company’s stock worth $606,000 after purchasing an additional 1,414 shares during the period. Finally, Demars Financial Group LLC grew its position in shares of Bristol Myers Squibb by 2.5% during the 3rd quarter. Demars Financial Group LLC now owns 31,764 shares of the biopharmaceutical company’s stock valued at $1,982,000 after acquiring an additional 787 shares during the period. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Insider Activity at Bristol Myers Squibb

In other news, SVP Phil M. Holzer sold 500 shares of the company’s stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total transaction of $33,750.00. Following the sale, the senior vice president directly owned 16,862 shares of the company’s stock, valued at $1,138,185. This represents a 2.88% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 0.05% of the company’s stock.

Bristol Myers Squibb Price Performance

Shares of NYSE:BMY traded down $1.42 during midday trading on Friday, reaching $61.58. 9,762,895 shares of the company were exchanged, compared to its average volume of 13,420,046. The stock has a market cap of $125.79 billion, a PE ratio of 13.56, a price-to-earnings-growth ratio of 0.32 and a beta of 0.19. The business’s fifty day moving average is $63.26 and its two-hundred day moving average is $60.33. Bristol Myers Squibb Company has a one year low of $42.52 and a one year high of $68.64. The company has a current ratio of 1.53, a quick ratio of 1.38 and a debt-to-equity ratio of 1.89.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.60 by $0.44. The company had revenue of $12.97 billion for the quarter, compared to the consensus estimate of $11.74 billion. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. Bristol Myers Squibb’s revenue for the quarter was up 5.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.46 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. As a group, analysts predict that Bristol Myers Squibb Company will post 6.56 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, November 2nd. Investors of record on Friday, October 2nd will be given a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.1%. The ex-dividend date is Friday, October 2nd. Bristol Myers Squibb’s payout ratio is currently 55.51%.

Bristol Myers Squibb News Summary

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers and SystImmune reported that izalontamab brengitecan reduced the risk of disease progression or death by 59% versus chemotherapy in the Phase 3 PANKU-Breast01 trial for advanced HR-positive/HER2-negative breast cancer. The result could strengthen BMY’s oncology pipeline and support a future regulatory filing. Bristol Myers, SystImmune drug cuts breast cancer progression risk in study
• Positive Sentiment: BMY expanded its multi-year collaboration with Tempus AI, licensing multimodal oncology data through 2031 to aid target discovery and drug development. Separately, BMS is collaborating with Pathos AI and Tempus on AI-driven research in Alzheimer’s disease and other neurological conditions, while leading Pathos’s Series E financing and gaining access to its Foundry platform. These deals may improve research productivity and pipeline potential, although financial benefits are longer term. Tempus Expands Strategic Collaboration with Bristol Myers Squibb Pathos AI Announces Strategic Collaborations
• Positive Sentiment: Analyst H. Engel modestly raised Erste Group’s FY2027 EPS forecast to $6.56 from $6.53, matching consensus and suggesting stable expectations for BMY’s earnings power. Bristol Myers Squibb analyst estimate update
• Neutral Sentiment: Phase 1 Breakfree-2 data for the CAR-T therapy zolacabtagene autoleucel in highly active multiple sclerosis provide another pipeline catalyst, but the early-stage study still requires larger and later-stage testing before its commercial value can be assessed. Bristol Myers Squibb Presents Breakfree-2 Results
• Negative Sentiment: Bristol Myers disclosed a patient death in the early-stage cell-therapy study. Even if the event does not ultimately change the program’s development, it introduces a safety overhang and may overshadow the positive efficacy data. Bristol Myers discloses patient death in early-stage cell therapy study
• Negative Sentiment: Pre-earnings coverage anticipates a year-over-year decline in third-quarter earnings, keeping attention on legacy-drug erosion, pipeline execution and BMY’s relatively high debt load. These concerns could outweigh the company’s inexpensive valuation and attractive dividend in the near term. Earnings Preview: Bristol Myers Squibb Q3 Earnings Expected to Decline

Wall Street Analysts Forecast Growth

BMY has been the subject of a number of recent research reports. Zacks Research downgraded Bristol Myers Squibb from a “strong-buy” rating to a “hold” rating in a research note on Thursday. JPMorgan Chase & Co. raised their price objective on shares of Bristol Myers Squibb from $67.00 to $73.00 and gave the company an “overweight” rating in a research report on Friday, July 31st. Royal Bank Of Canada reaffirmed a “sector perform” rating on shares of Bristol Myers Squibb in a report on Monday. Argus raised Bristol Myers Squibb from a “hold” rating to a “buy” rating and set a $75.00 price target on the stock in a report on Wednesday, August 5th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a $76.00 price objective on shares of Bristol Myers Squibb in a research note on Monday, October 12th. Two research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, sixteen have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Bristol Myers Squibb has an average rating of “Hold” and a consensus target price of $64.88.

Bristol Myers Squibb Profile

Bristol Myers Squibb (NYSE:BMY) is a global biopharmaceutical company focused on discovering, developing and commercializing medicines for serious diseases. Its research and development activities span oncology, hematology, immunology, cardiovascular disease, neuroscience and other specialty areas.

The company’s portfolio includes oncology medicines such as Opdivo, Yervoy, Abraxane, Sprycel and Pomalyst, as well as Eliquis, an anticoagulant developed in partnership with Pfizer. Bristol Myers Squibb also markets immunology and neuroscience products, including Orencia and Sotyktu, and continues to invest in therapies based on biologics, cell therapy and other advanced treatment approaches.

Bristol Myers Squibb traces its roots to pharmaceutical businesses founded by Bristol-Myers in 1881 and E.R.